Oruka Therapeutics (ORKA) Equity Ratio (2010 - 2026)

Oruka Therapeutics' Equity Ratio history runs 17 years deep, the most recent figure standing at 0.96 for Q1 2026.

• In Q1 2026, Equity Ratio changed 0.24% year-over-year to 0.96; the TTM figure through Mar 2026 stood at 0.96 (changed 0.24% YoY), while the FY2025 annual figure was 0.97, changed 0.07% from the prior year.
• Equity Ratio was 0.96 for Q1 2026 at Oruka Therapeutics, roughly flat from 0.97 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.98 in Q4 2023 to a low of 0.86 in Q2 2024.
• Historically, Equity Ratio has averaged 0.78 across 5 years, with a median of 0.96 in 2025.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio plunged 189.66% in 2024, then surged 602.91% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.97 in 2022, then advanced by 1.09% to 0.98 in 2023, then decreased by 1.29% to 0.97 in 2024, then rose by 0.07% to 0.97 in 2025, then retreated by 0.11% to 0.96 in 2026.
• The last three Equity Ratio figures came in at 0.96 (Q1 2026), 0.97 (Q4 2025), and 0.96 (Q3 2025), per Business Quant data.